Avai Bio, Austrianova reach deal with partner to supply insulin-producing cells for Insulinova diabetes therapy
AVAI•Insulinova program and next steps
Insulinova, formed in late 2025, is a joint venture between Avaí Bio and Austrianova to develop an implantable diabetes cell therapy.
The program pairs programmed insulin-producing cells with Austrianova’s Cell-in-a-Box encapsulation technology to enable glucose-responsive insulin production.
Definitive agreements remain subject to execution, with closing conditions expected to be completed in the coming days.
Deal to supply insulin-producing cells
Avai Bio reached terms with Austrianova on a collaboration with an unnamed international partner to supply insulin-producing cells for Insulinova.
